Cynthia Xiuguang Ma MD Ph.D.

Oncology•St. Louis, MO

Breast Cancer, Hematologic Oncology

Professor, Internal Medicine, Washington University in St. Louis School of Medicine

Join to View Full Profile

4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192

Summary

Medical oncologist specializing in breast cancer and a physician-scientist experienced in clinical/translational research in the area of breast cancer biomarkers and molecular targeted treatment strategies.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2001 - 2005
Novant Health New Hanover Regional Medical CenterResidency, Internal Medicine, 1998 - 2001
University of CincinnatiPhD, Developmental Biology, 1997
Beijing Medical UniversityClass of 1990

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 2005 - 2026
MN State Medical License 2001 - 2006
NC State Medical License 1998 - 2001
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

NCI Cancer Clinical Investigator Team Leadership Award NCI, 2013
CALGB Clinical Scholar Award CALGB Foundation, 2011
ASCO Career Development Award ASCO, 2008
Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Join now to see all

Clinical Trials

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Start of enrollment: 2001 Dec 01
Completed
Phase 1
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction Start of enrollment: 2005 Aug 01
Completed
Phase 2
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer Start of enrollment: 2006 Mar 01
Terminated
Phase 2
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
RECRUITING
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2008 Oct 31
Completed
Phase 1, Phase 2
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
COMPLETED
PHASE2
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer Start of enrollment: 2010 Jun 30
COMPLETED
PHASE2
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer Start of enrollment: 2011 Nov 14
Completed
Phase 1
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer Start of enrollment: 2011 Apr 21
Completed
Phase 1
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 May 02
ACTIVE_NOT_RECRUITING
PHASE1
Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer Start of enrollment: 2012 Sep 01
Withdrawn
Phase 2
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Start of enrollment: 2013 Apr 10
ACTIVE_NOT_RECRUITING
PHASE2
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Withdrawn
Phase 2
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19
Terminated
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
Withdrawn
Phase 2
Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery Start of enrollment: 2014 Feb 27
ACTIVE_NOT_RECRUITING
PHASE3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07
Terminated
Phase 2
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2017 Jun 15
Completed
Phase 2
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer Start of enrollment: 2018 Aug 07
Withdrawn
Phase 2
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer Start of enrollment: 2020 Jun 17
ACTIVE_NOT_RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, Rinath Jeselsohn, Reshma L Mahtani
Clinical Cancer Research. 2025-11-03
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Co...
Letizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, Arielle J Medford, Judy Wang
NPJ Breast Cancer. 2025-08-16
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.
Komal Jhaveri, Carey K Anders, Aditya Bardia, Manali Bhave, A Jo Chien
Clinical Breast Cancer. 2025-08-01

Journal Articles

Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts
Souzan Sanati, Jana W Qiao, Xian Chen, Matthew J Ellis, Cynthia Ma, Nature

Other

Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy
Ma CX, Ellis M, Naughton MJ
http://www.uptodate.com/contents/treatment-approach-to-metastatic-hormone-receptor-positive-breast-c
UpToDate, Wolters Kluwer Health - 2013-01-16

Press Mentions

Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast CancerFebruary 23rd, 2023
Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient PopulationsJune 4th, 2021
Salvage Neoadjuvant Chemo Induces “Very Low” Pathologic Complete Response RateDecember 11th, 2020
Join now to see all

Grant Support

Regulation of resistance to CDK4/6 inhibitor in breast cancerGEORGE WASHINGTON UNIVERSITY2023–2028
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancerWASHINGTON UNIVERSITY2022–2027
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancerWASHINGTON UNIVERSITY2022–2027
Washington University Co-Clinical Imaging Research ResourceWASHINGTON UNIVERSITY2017–2027
Washington University Co-Clinical Imaging Research ResourceWASHINGTON UNIVERSITY2017–2027

Committees

Member, Medical Oncologist Commimttee, ACOSOG 2009 - 2012
Member, Institutional Review Board of Human Research, Washington University 2006 - 2015
Member, CALGB Breast Cancer Committee 2006 - 2012

Research History

Principal InvestigatorPuma Biotechnology A Phase II Study of Neratinib in Metastatic HER2 Mutated Non-Amplified Breast Cancer.2013 - Present
Principal InvestigatorPfizer Pharmaceutical Inc. A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 inhibitor, in Combination with Anastrozole in Women with Clinical Stage II or III Estrogen Receptor Positive and HER2 Negative Breast Cancer.2013 - Present
Principal InvestigatorBreast Cancer Research Foundation The ALTERNATE Trial: A Biomarker Directed Approach in the management of postmenopausal women with linical stage II or III Estrogen Receptor Positive breast cancer.2016 - 2018
Principal InvestigatorEisai Pharmaceuticals Efficacy of Eribulin in Combination with Buparlisib in PDX models of TNBC2016 - 2018